Akari shareholders approve warrant exercises and share issuances at special meeting

Akari Therapeutics Plc

Shareholders voted overwhelmingly to approve exercisability of Series G, Placement Agent, Pre-Funded, and Note Exchange warrants.
Proposals covered up to ~10M ADSs from Series G/Placement Agent warrants and ~19M ADSs from Pre-Funded/Note Exchange warrants.
All five resolutions passed with over 99% of votes cast in favor; abstentions negligible.
Meeting held March 2, 2026; matters related to capital raises and note exchanges from Dec 2025 and Jan 2026.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.